Brand & Product Security

Articles

Data from the Phase III APPLAUSE-IgAN study showed a 38.3% reduction in proteinuria in patients treated with Fabhalta for IgA nephropathy compared to placebo. 

Novartis’ Fabhalta Shows Significant Promise in Reducing Proteinuria in Patients with IgA Nephropathy 

Phase IIa clinical trial of SPG60 for Fragile X syndrome offers hope for disease with no current FDA-approved treatment options.

Spinogenix’s Investigational New Drug Application for Novel Treatment for Fragile X Syndrome Cleared to Begin Phase II Trial

A cohort study digs into whether there is an improvement in overall survival or quality of life within five years of the FDA granting accelerated approval to oncology drugs. 

Evaluating the Long-Term Clinical Benefit of Cancer Treatments Granted Accelerated Approval

Cross-sectional study explores the impact of this monumental Supreme Court ruling. 

How Dobbs v Jackson Women’s Health Organization Decision Influenced Self-Management Medication Use

Exploring how current and future legislation may impact the role of pharmacy benefit managers (PBMs).


What Will Change in the Pharma  Industry Look Like?

A study investigates how a New Mexico law can impact patients’ out-of-pocket costs surrounding mental health and substance use disorder medications. 

Does the Passing of a No Behavioral Health-Cost Sharing Law Have Any Bearing on Spending?

Conference’s opening session addresses the evolving landscape of healthcare coverage and accessibility.

Access USA 2024: The State of the Industry

Xhance is the first medication indicated for the treatment of chronic rhinosinusitis without nasal polyps to be approved by the FDA. 

FDA Approves Xhance, Optinose’s Treatment for Adults with Chronic Rhinosinusitis Without Nasal Polyps 

Approval was based on positive data from the Phase III MARCH study across a range of genetic progressive familial intrahepatic cholestasis types. 

FDA Expands Approval of Mirum’s Livmarli for Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis

A proposed Senate bill is intended to protect citizens’ private health and genetic information.

Legal & Regulatory